



Medicines Formulary Assessments

Otigo® Ear Drops for otitis media—Otigo® is an ear drop containing an analgesic and anaesthetic (phenazone/lidocaine) for relief of ear pain in otitis media. Evidence from the CEDAR Trial has been assessed and the decision was taken to not support routine prescribing of Otigo® due to insufficient quality evidence to support efficacy.

Potassium Permanganate (PP) for cleansing and deodorising suppurating eczematous reactions and wounds

The publication of the [NPSA Alert—Inadvertent oral administration of PP](#) prompted a review of Formulary position. There will be no change (remains Green) due to unique and valuable place in therapy. Safety messages have been deployed to highlight risks.

Gonadorelins Formulary Review (Zoladex®, Prostag®, Gonapeptyl®, Decapeptyl®)

In June, a full section review of the gonadorelins was undertaken with subsequent addition of all products to the Formularies as Amber/Amber 1). BLMK have also developed a prescribing aid containing the available products and their licensed indications. See [link for table](#).

Buccal Midazolam preparations for treatment of prolonged, acute, convulsive seizures

Formulary entries have been updated with the following information:

- Buccolam® remains the first choice product, which is available in 2.5mg, 5mg, 7.5mg and 10mg fixed doses as a Pre-filled syringe (not graduated for part doses).
- For patients who cannot receive a fixed Buccolam® dose, Epistatus® multi dose bottle (unlicensed special) has been added to the Formularies (Amber/Amber1). The required dosage can be withdrawn from the bottle of solution.
- All strengths of Epistatus® Pre-filled syringes (unlicensed) are now Non-Formulary. Existing patients may continue if it is not appropriate to switch to Buccolam®.
- Products must be prescribed by brand name to reduce risk of medication errors.
- Care should be taken when switching as Buccolam® is half the strength of Epistatus® (e.g. 10mg in 2mL vs. 10mg in 1mL).

Tizanidine for spasticity in Multiple Sclerosis

- Tizanidine is used to relieve the spasms and increased muscle tone caused by multiple sclerosis. It is now on the Formulary (Amber/Amber3)
- The 2mg tablets should be prescribed (avoiding 4mg) due to a large difference in cost. An equivalent dosage costs approximately 3 times as much when prescribed using 4mg tablets.

Actimorph® tablets (Schedule 2 CD)

Actimorph® is an orodispersible immediate release morphine tablet licensed for severe pain. Addition to the Formularies (Green) as an alternative option to morphine oral solution.

Minor Updates

- **Tramadol MR tablets (Marol)** - Added to Formulary (Green)
- **Modafinil, dexamfetamine, methylphenidate**—updated to include narcolepsy and cataplexy indication under SCG
- **Clomipramine, venlafaxine** – Amber / Amber 3 for narcolepsy and cataplexy in line with EoE PAC guidance
- **Sitagliptin** now first line DPP4 inhibitor in line with current Prescribing Incentive Scheme
- **Haloperidol 500mcg tablets** removed due to large price rise. Now recommending oral solution as alternative
- **Rinatec** has updated brand name to Rinaspray – Formulary updated (currently unavailable)
- **Elleste Solo MX patches** have been discontinued

Is there a medicine you would like added to the Bedford, Luton and Milton Keynes Joint Formulary?

Email us via bedccg.bedsmeds@nhs.net to discuss how

